Skip to main content

Table 3 Risk ratio (95% CI) of specific adverse effects between different treatment groups

From: Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials

Comparison

GI AE

CV AE

CNS AE

MU AE

Infection

Skin AE

Others

G vs PBO

0.99(0.79, 1.23)

NA

0.72(0.46, 1.10)

1.52(0.88, 2.63)

1.07(0.50, 2.32)

0.80(0.38, 1.68)

1.21(0.98, 1.48)

C vs PBO

0.35(0.14, 0.87)

1.13(0.45, 2.84)

0.79(0.37, 1.67)

NA

0.98(0.72, 1.34)

1.00(0.41, 2.45)

NA

G + C vs PBO

2.79(0.30, 26.00)

NA

1.86(0.36, 9.74)

2.79(0.30, 26.00)

2.79(0.12, 67.10)

NA

4.66(0.23, 94.79)

Overall

0.92(0.74, 1.13)

1.13(0.45, 2.84)

0.77(0.54, 1.11)

1.58(0.93, 2.70)

1.01(0.76, 1.35)

0.88(0.50, 1.55)

1.22(1.00, 1.50)

  1. G glucosamine, C chondroitin, G + C glucosamine + chondroitin, PBO placebo, NA not available, GI gastrointestinal, CV cardiovascular, CNS central nervous system, MU musculoskeletal